Zipari has raised $22.5m from Horizon Healthcare Services and CareFirst BlueCross BlueShield among others to boost its total to $33.9m.

Subsidiaries of Astellas and Novartis co-led a series B round that took Harvard's cancer treatment developer's overall funding to $60m.

Pavilion Capital and Hansjörg Wyss featured in a series B round for Harvard-founded ReadCoor, whose existing shareholders also include Lilly Asia Ventures.

Fusion Pharmaceuticals has now raised $171m altogether to deliver cancer radiopharmaceuticals based on McMaster University research.

Canada Pension Plan Investment Board has pledged up to $20m for the Varian Medical and Johnson & Johnson-backed oncology drug developer.

Eli Lilly-backed ReadCoor took its total funding to $50m and will use the funding to commercialise its gene sequencing technology.

Proceeds from the Telstra Ventures-led series B round will allow Corvus to accelerate insurance technology development and build tools to improve its risk management.

The remittance services startup raised $31.2m from backers including HashKey, UOB, Seven Bank, Uni-President Enterprises and Hanwha.

Mayo Clinic has bet on chronic disease drug developer Novome Biotechnologies, which is initially targeting a disorder known as hyperoxaluria.

Line Ventures backed a $36.2m round for AI-equipped e-commerce platform TimeBank that will help the startup acquire new users and partners.